Image

Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision

Recruiting
6 - 18 years of age
Both
Phase N/A

Powered by AI

Overview

Background

CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years. Researchers want to test an assistive device that may help children with CLN3 or blindness.

Objective

To learn if it is safe, easy, and useful for children with CLN3 or blindness to use the OrCam.

Eligibility

People aged 6-18 years who have either CLN3-related disease or blindness.

Design

Participants will be screened with the following:

Medical history

Physical exam

Family history

Eye exam and vision tests. They will get eyedrops to dilate their eyes.

Psychological and neurocognitive tests. They will be asked questions and observed for how they do various tasks, such as talking, playing, writing, drawing, and solving problems.

Hearing tests. They may wear headphones or earplugs. Electrodes may be taped to their head.

Blood samples

Skin biopsy, if needed

Cheek cell, saliva, or urine samples

The OrCam is the size of and weighs about half as much as a pack of gum. It is attached to eyeglass frames by magnets. Participants will do tasks before and after they have been trained on the OrCam. They will do these tasks without or with using the OrCam.

Participants will be given an OrCam to use for 1 week or 1 month. They will have check-in sessions with the study team.

Participants and/or their caregivers will be asked about abilities, behaviors, social skills, learning methods, intelligence, and health-related quality of life.

Participants samples may be used for genetic testing and/or to make a type of stem cell.

Participation will last for 1-5 weeks.

Description

Study Description:

This is a pilot study of an augmentative visual device, OrCam MyEye 2 (OrCam), in pediatric individuals with CLN3-related conditions or low vision. We hypothesize that, given the relatively simple design and operating procedure of the device, the use of the OrCam by study participants will be safe and feasible. We also hypothesize that the device will enhance their ability to obtain visually based information.

Objectives
Primary

Assess the safety and feasibility of OrCam use by children with CLN3 or low vision.

Secondary

Assess the effectiveness of OrCam use by children with CLN3 or low vision.

Exploratory

Assess the feasibility and effectiveness of OrCam use in CLN3 versus non-CLN3 groups. Optimize methods for assessing efficacy of visual accommodation/assistive devices for the CLN3/NCL population

Endpoints
Primary
  1. Adverse events during the use of OrCam. 2) Feasibility test. 3) Feasibility questionnaire.
  2. Device use diary. The assessment periods will be 1 week at study site and 1 month at home.
Secondary
  1. Function test of using OrCam. 2) Ability questionnaire.
Exploratory
  1. Function test. 2) Feasibility, Ability, Applicability questionnaires.

Eligibility

  • INCLUSION CRITERIA:
        To participate in the screening portion of this study, an individual must meet all of the
        following criteria:
        -Has a diagnosis or suspected diagnosis of any genetically based condition causing low
        vision to the level specified in criteria 2.
        If the genetic condition is CLN3-related, the individual must have one of the following:
          -  Two CLN3 pathogenic variants,
          -  One CLN3 pathogenic variant AND
               -  clinical presentation suggestive of CLN3, OR
               -  characteristic electron microscopy (EM) findings (such as curvilinear body,
                  fingerprint profile, granular osmiophilic deposits).
                    -  Has an estimated visual acuity in the better seeing eye < 20/200, without
                       the use of an assistive or augmentative device.
                    -  Is between 6 to 18 years of age.
                    -  To participate in the intervention/device use portion of this study, an
                       individual must meet the above screening criteria and the following
                       criteria:
          -  Has an appropriate cognitive developmental ability to participate based on
             Investigators screening assessment.
        EXCLUSION CRITERIA:
        An individual who meets any of the following criteria will be excluded from participation
        in this study:
          -  Has any of the following auditory dysfunctions: non-reversible or non-correctable
             hearing loss, tinnitus that is chronic or occurring daily, auditory hallucinations
             that occur daily.
          -  Uses an optic-to-audio assistive device at the time or within 3 months of screening
             and enrollment.
          -  Is unable to travel to the NIH because of medical condition for required in-person
             portions of the study.
          -  Is unable to comply with or have medical conditions that would potentially increase
             the risk of participation.

Study details

CLN3-related Disorders, Low Vision

NCT04974307

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.